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Table 1
Sex (M/F) 98/102
Median age 51 (18-72)
Age > 50 53%
KPS > 80% 64%
HCT-CI Score >4 19%
Figure 1A. Progression-free survival.
Figure 1B. Cumulative incidence of relapse for FiT3+ve pts by disease status at
transplant.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S82(Table1). All donor sources were included: 63 matched
sibling (MSD), 95 10/10 MUD, 11 9/10 MUD, 18 cord blood
(CB), and 13 haploidentical (Haplo).
Results: The majority of pts received myeloablative condi-
tioning (n¼170; busulfan-based n¼148). Disease status at
AlloSCT was: CR1 (n¼99), CR2 (n¼20), CR with incomplete
count recovery or hypoplasticmarrowor CR3 (CRi; n¼31), and
active disease (AD; n¼50). Thirty percent of pts received a FLT3
inhibitorbeforeAlloSCT.After amedian follow-upof27mo, the
2-year (2Y) OS and PFS rates were 43% and 41%, respectively.
Relapse-related mortality was the main cause of death (68%).
Remission and FLT3 status at the time of AlloSCT were signiﬁ-
cantly associated with PFS. Compared to CR1 pts, PFS was not
different inCR2 [HR1.5, p¼0.3], but itwasworse inCRi (HR3.9,
p<0.001)andADpts (HR5.9, p<0.001). The2YPFSwashighest
inCR1/2FLT3evepts (62%) compared to theothergroups:CR1/
2 FLT3+ve (41%, p¼0.3); CRi FLT3eve (33%, p¼0.01); CRi
FLT3+ve (0%, p<0.001); AD (8% p<0.001) (Figures 1A, 1B). On
multivariate analysis, independent predictors of worse PFS
included: AD [HR 4.5, p<0.001], CRi FLT3+ve [HR 7.2,
p<0.001], KPS80 [HR2.1, p<0.001], HCT-CI>4 [HR 1.6,
p¼0.05], and unrelated donor source [HR 1.6, p¼0.05]. No
difference in PFS was found between Haplo and MSD donor
sources (HR¼0.9, p¼0.9). No signiﬁcant association wasidentiﬁed by age, conditioning intensity or use of a FLT3
inhibitor prior to transplant. Post-transplant FLT3 status was
available for 105 of 190 evaluable pts by day 30. Among
them, 7ptshaddetectable FLT3PCR and5/7 pts (71%) relapsed.
Conclusion: Morphologic remission and FLT3 PCR status at
the time of transplant are key predictors of relapse risk in pts
with FLT3+ AML. Patients who achieved a morphologic CR
with an undetectable FLT3 by PCR at the time of SCT had the
best outcomes and should undergo an AlloSCTwithout delay.
Although the experience is limited, Haplo transplants had
similar outcomes to MSD transplants. Prospective clinical
trials with FLT3 inhibitors post-transplant are warranted at
least for pts with AD or persistent FLT3+ on PCR at transplant.
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Introduction: There are limited data on the impact of he-
matopoietic stem cell transplant (HSCT) conditioning
regimen, especially without total body radiation (TBI) in
pediatric patients with acute lymphoblastic leukemia (ALL)
with central nervous system (CNS) involvement. The aim of
this study is compare the results of HSCT using non-TBI
conditioning regimen in ALL patients aged18 years with or
without CNS involvement.
Patients and Methods: Records of 183 patients with ALL
(128 male; 55 female) with a median age of 14.13.7 years
who had undergone HSCT were studied and classiﬁed in two
groups: with and without CNS involvement. Long-term
consequence of the HSCT consisting of leukemia free survival
(LFS), the overall survival (OS), relapse and transplant-
related mortality (TRM) was compared in the two groups.
Results: A total of 183 ALL patients (148 without CNS
involvement and 35 with CNS involvement) underwent
HSCT in our center using a TBI-free conditioning containing
Busulfan and Cyclophosphomide. The median time of follow
up was 42.1 months. Estimated probability on relapse at 4
year was 51.4% in patients with CNS involvement and 42.1%
in patients without CNS involvement (p¼0.588). Regarding
survival analysis, 4-year OS and LFS in all patients was 44.4%
(SE:2.5%) and 39.7%(SE:2.5%). In multivariate analysis there
were no signiﬁcant differences in OS and LFS between two
groups (p¼0.839, p¼894) nor was there a difference in
relapse probability (HR:1.20, 95%CI:0.69-2.1, p¼0.513) and
TRM (HR:0.44, 95%CI:0.10-1.92, p¼0.286).
Conclusion: HSCT using a non TBI conditioning regimen in
ALL are similar with studies using TBI containing regimens.
Furthermore HSCT leads to similar clinical outcomes and
long-term survival in the ALL pediatric patients with or
without CNS involvement.
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